One line to note in the announcement is :
The final module will be filed during January, and Mesoblast will request an expedited FDA review of the BLA under the product candidate’s existing Fast Track designation. If approved, remestemcel-L is planned to be launched in the US in 2020.
That could mean next week or the week after even ? Doesn't necessarily mean we will have to wait the entire month of January IMO
GLTAH
MSB Trading - 2020, page-7
-
- There are more pages in this discussion • 23,154 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.025(2.51%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 97.0¢ | $1.01 | 96.5¢ | $7.757M | 7.884M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 274918 | 97.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.5¢ | 974 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |